SFCM
RLMD icon

Seven Fleet Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Seven Fleet Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.41M Buy
+348,265
New +$2.43M 0.4% 39
2026
Q1 		– Sell
-154,109
Closed -$744K – 134
2025
Q4 		$744K Buy
+154,109
New +$516K 0.5% 38

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Seven Fleet Capital Management's RLMD Position: Q2 2026 in Review

Seven Fleet Capital Management opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 348,265 shares worth $2.41M. The stake represents 0.4% of the portfolio and ranks #39 among its holdings. This is a return to the name: Seven Fleet Capital Management previously reported a position in RLMD as recently as Q4 2025.

Seven Fleet Capital Management first reported a position in RLMD in Q4 2025 and has held it in 2 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Seven Fleet Capital Management held 348,265 shares of Relmada Therapeutics worth $2.41M as of Q2 2026.
  • Relmada Therapeutics was a new Seven Fleet Capital Management position in Q2 2026.
  • Relmada Therapeutics made up 0.4% of Seven Fleet Capital Management's portfolio in Q2 2026, its #39 holding.
  • Seven Fleet Capital Management first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Seven Fleet Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.